celecoxib has been researched along with Cancer of Esophagus in 31 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study the feasibility of chemoprevention of esophageal adenocarcinoma by celecoxib, a selective cyclooxygenase-2(COX-2) inhibitor using a rat model." | 7.78 | [An experimental study on chemoprevention of esophageal adenocarcinoma by celecoxib, a selective cyclooxygenase-2 inhibitor]. ( Lang, HJ; Liang, XH; Su, LW; Wang, YJ; Zhang, F; Zhang, T; Zhou, YA; Zhu, YF, 2012) |
| " We examined the effects of celecoxib, a COX-2 inhibitor, in enhancing the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma (ESCC) by reducing the COX-2 activity." | 3.80 | A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma. ( Akanuma, N; Akutsu, Y; Hanari, N; Hoshino, I; Hu, X; Isozaki, Y; Komatsu-Akimoto, A; Matsubara, H; Mori, M; Mutallip, M; Qin, W; Yusup, G, 2014) |
| "To study the feasibility of chemoprevention of esophageal adenocarcinoma by celecoxib, a selective cyclooxygenase-2(COX-2) inhibitor using a rat model." | 3.78 | [An experimental study on chemoprevention of esophageal adenocarcinoma by celecoxib, a selective cyclooxygenase-2 inhibitor]. ( Lang, HJ; Liang, XH; Su, LW; Wang, YJ; Zhang, F; Zhang, T; Zhou, YA; Zhu, YF, 2012) |
| "Although evidence suggests that aspirin and celecoxib may reduce the risk of esophageal adenocarcinoma (EAC) in patients with Barrett's esophagus (BE), these drugs can also cause harmful side effects." | 3.74 | Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus. ( Broughton, DE; Gazelle, GS; Hur, C; Nishioka, NS; Ozanne, E; Yachimski, P, 2008) |
| "A series of 90 rats underwent a duodenoesophageal reflux surgery were divided into 2 groups: the control group was given a commercial chow and the celecoxib group experimental chow containing celecoxib." | 3.73 | [A COX-2 inhibitor suppresses esophageal inflammation-metaplasia-adenocarcinoma sequence in rats]. ( Fujimura, T; Miwa, K; Oyama, K, 2005) |
| "To evaluate the effects of neoadjuvant therapy with the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib in vitro and in patients with esophageal adenocarcinoma on COX-2 and MET expression." | 3.73 | Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma. ( Buskens, CJ; Kemper, K; Offerhaus, GJ; Richel, DJ; ten Kate, FJ; Tuynman, JB; van Lanschot, JJ, 2005) |
| "Celecoxib 400 mg was taken orally twice daily during chemoradiation, up to 1 week before surgery, and for 6 months following surgery." | 2.82 | Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer. ( Bueno, R; Choi, N; Cleary, JM; Donahue, DM; Enzinger, PC; Fidias, PM; Fuchs, CS; Gaissert, HA; Jaklitsch, MT; Kulke, MH; Lynch, TP; Mamon, HJ; Mentzer, SJ; Meyerhardt, JA; Swanson, RS; Szymonifka, J; Wain, J, 2016) |
| "Celecoxib was given daily during CRT at one of five doses (200 mg bd to 600 mg bd)." | 2.73 | A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. ( Biagi, J; Dawson, SJ; Foo, KF; Hui, A; Jefford, M; Leong, T; Michael, M; Milner, AD; Ngan, SY; Thomas, RJ; Zalcberg, JR, 2007) |
| " Because aspirin and other nonsteroidal anti-inflammatory drugs, such as celecoxib, may decrease the risk of developing esophageal cancer, we investigated the effect of long-term administration of celecoxib in patients with Barrett's esophagus with dysplasia." | 2.73 | Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. ( Canto, MI; Dannenberg, AJ; Forastiere, AA; Hawk, E; Heath, EI; Herman, JG; Montgomery, E; Piantadosi, S; Shar, AO; Weinstein, WM; Yang, VW, 2007) |
| "Celecoxib (Celebrex) was administered at 200 mg orally twice daily beginning on day 1 until surgery and then at 400 mg orally twice daily until disease progression or unexpected toxicities, or for a maximum of 5 years." | 2.71 | Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results. ( Ansari, R; Fineberg, N; Fox, E; Govindan, R; Hanna, N; Helft, P; Kesler, K; Mantravadi, P; McLeod, H; Stoner, C, 2004) |
| "Esophageal squamous cell carcinoma remains a leading cause of cancer death worldwide." | 2.71 | Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib. ( Ahnen, DJ; Caldwell, KL; Dawsey, SM; Dong, Z; Giffen, CA; Hawk, ET; Korn, EL; Limburg, PJ; Lu, N; Ma, Y; Qiao, Y; Roth, MJ; Taylor, PR; Wang, G; Wei, W, 2005) |
| "Capecitabine is an oral 5-fluorouracil (5-FU) prodrug that is more convenient than using infusional 5-FU, appears to have a similar therapeutic profile, and can be combined with daily irradiation." | 2.42 | COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas. ( Rich, TA; Shepard, R, 2003) |
| "Celecoxib treatment significantly increased the IC50 of carboplatin, suppressed carboplatin-induced caspase-3 and PARP cleavage and caspase-3 activity in EC109 and EC109/CDDP cells." | 1.40 | [Celecoxib antagonizes the cytotoxic effect of carboplatin in human esophageal cancer cells]. ( Gu, C; Shi, L; Yu, L; Zhong, D, 2014) |
| "Celecoxib treatment decreased the incidence of EA in rats undergoing EJA with H." | 1.37 | Effect of Helicobacter pylori infection on Barrett's esophagus and esophageal adenocarcinoma formation in a rat model of chronic gastroesophageal reflux. ( Gao, PP; Li, J; Liu, FX; Wang, J; Wang, WH, 2011) |
| "examined Barrett's esophagus patient preferences for cancer chemoprevention with either aspirin or celecoxib." | 1.35 | Chemoprevention and Barrett's esophagus: decisions, decisions. ( Falk, GW; Jankowski, J, 2008) |
| "Esophageal and tongue cancers have both been associated with dietary zinc deficiency (ZD), and cyclooxygenase (COX-2) is often overexpressed in these cancers." | 1.33 | Dietary zinc modulation of COX-2 expression and lingual and esophageal carcinogenesis in rats. ( Farber, JL; Fong, LY; Jiang, Y; Zhang, L, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (54.84) | 29.6817 |
| 2010's | 13 (41.94) | 24.3611 |
| 2020's | 1 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Noronha, V | 1 |
| Patil, VM | 1 |
| Menon, NS | 1 |
| Joshi, A | 1 |
| Goud, S | 1 |
| More, S | 1 |
| Kannan, S | 1 |
| Pawar, A | 1 |
| Nakti, D | 1 |
| Yadav, A | 1 |
| Shah, S | 1 |
| Mahajan, A | 1 |
| Janu, A | 1 |
| Kumar, R | 1 |
| Tibdewal, A | 1 |
| Mummudi, N | 1 |
| Agarwal, JP | 1 |
| Banavali, SD | 1 |
| Prabhash, K | 1 |
| Liu, J | 1 |
| Qin, CK | 1 |
| Lv, W | 1 |
| Zhao, Q | 1 |
| Qin, CY | 1 |
| Yusup, G | 1 |
| Akutsu, Y | 1 |
| Mutallip, M | 1 |
| Qin, W | 1 |
| Hu, X | 1 |
| Komatsu-Akimoto, A | 1 |
| Hoshino, I | 1 |
| Hanari, N | 1 |
| Mori, M | 1 |
| Akanuma, N | 1 |
| Isozaki, Y | 1 |
| Matsubara, H | 1 |
| Shi, L | 1 |
| Zhong, D | 2 |
| Gu, C | 2 |
| Yu, L | 3 |
| Kong, Y | 1 |
| Zhao, X | 1 |
| Lin, Q | 1 |
| Wang, K | 1 |
| Xun, T | 1 |
| Liu, S | 2 |
| Liu, JF | 1 |
| Li, YS | 1 |
| Drew, PA | 1 |
| Zhang, C | 1 |
| Cleary, JM | 1 |
| Mamon, HJ | 1 |
| Szymonifka, J | 1 |
| Bueno, R | 1 |
| Choi, N | 1 |
| Donahue, DM | 1 |
| Fidias, PM | 1 |
| Gaissert, HA | 1 |
| Jaklitsch, MT | 1 |
| Kulke, MH | 1 |
| Lynch, TP | 1 |
| Mentzer, SJ | 1 |
| Meyerhardt, JA | 1 |
| Swanson, RS | 1 |
| Wain, J | 1 |
| Fuchs, CS | 1 |
| Enzinger, PC | 1 |
| Falk, GW | 1 |
| Jankowski, J | 1 |
| Hur, C | 1 |
| Broughton, DE | 1 |
| Ozanne, E | 1 |
| Yachimski, P | 1 |
| Nishioka, NS | 1 |
| Gazelle, GS | 1 |
| Beales, IL | 1 |
| Ogunwobi, OO | 1 |
| Roth, MJ | 2 |
| Katki, HA | 1 |
| Wei, WQ | 2 |
| Qiao, YL | 2 |
| Bagni, R | 1 |
| Wang, GQ | 1 |
| Whitby, D | 1 |
| Dong, ZW | 2 |
| Gail, MH | 1 |
| Limburg, PJ | 3 |
| Giffen, CA | 2 |
| Taylor, PR | 3 |
| Dawsey, SM | 3 |
| Triadafilopoulos, G | 1 |
| Lombard, CM | 1 |
| Jobe, BA | 1 |
| Chen, M | 1 |
| Li, Z | 1 |
| Wen, J | 1 |
| Fu, J | 1 |
| Guo, D | 1 |
| Jiang, Y | 3 |
| Wu, S | 1 |
| Cho, CH | 1 |
| Liu, FX | 1 |
| Wang, WH | 1 |
| Wang, J | 1 |
| Li, J | 1 |
| Gao, PP | 1 |
| Altorki, NK | 1 |
| Christos, P | 1 |
| Port, JL | 1 |
| Lee, PC | 1 |
| Mirza, F | 1 |
| Spinelli, C | 1 |
| Keresztes, R | 1 |
| Beneck, D | 1 |
| Paul, S | 1 |
| Stiles, BM | 1 |
| Zhang, Y | 1 |
| Schrump, DS | 1 |
| Zhang, T | 1 |
| Su, LW | 1 |
| Zhu, YF | 1 |
| Lang, HJ | 1 |
| Zhang, F | 1 |
| Zhou, YA | 1 |
| Liang, XH | 1 |
| Wang, YJ | 1 |
| Liao, Z | 1 |
| Milas, L | 1 |
| Komaki, R | 1 |
| Stevens, C | 1 |
| Cox, JD | 1 |
| Rich, TA | 1 |
| Shepard, R | 1 |
| Chen, X | 1 |
| Wang, S | 1 |
| Wu, N | 1 |
| Sood, S | 1 |
| Wang, P | 1 |
| Jin, Z | 1 |
| Beer, DG | 1 |
| Giordano, TJ | 1 |
| Lin, Y | 1 |
| Shih, WC | 1 |
| Lubet, RA | 1 |
| Yang, CS | 1 |
| Bardou, M | 1 |
| Barkun, AN | 1 |
| Ghosn, J | 1 |
| Hudson, M | 1 |
| Rahme, E | 1 |
| Fong, LY | 2 |
| Zhang, L | 1 |
| Farber, JL | 2 |
| Govindan, R | 1 |
| McLeod, H | 1 |
| Mantravadi, P | 1 |
| Fineberg, N | 1 |
| Helft, P | 1 |
| Kesler, K | 1 |
| Hanna, N | 1 |
| Stoner, C | 1 |
| Ansari, R | 1 |
| Fox, E | 1 |
| Graepler, F | 1 |
| Gregor, M | 1 |
| Lauer, UM | 1 |
| Miwa, K | 1 |
| Oyama, K | 1 |
| Fujimura, T | 1 |
| Wei, W | 1 |
| Ahnen, DJ | 1 |
| Qiao, Y | 1 |
| Hawk, ET | 2 |
| Wang, G | 2 |
| Lu, N | 1 |
| Korn, EL | 1 |
| Ma, Y | 1 |
| Caldwell, KL | 1 |
| Dong, Z | 1 |
| Tuynman, JB | 1 |
| Buskens, CJ | 1 |
| Kemper, K | 1 |
| ten Kate, FJ | 1 |
| Offerhaus, GJ | 1 |
| Richel, DJ | 1 |
| van Lanschot, JJ | 1 |
| Joshi, N | 1 |
| Johnson, LL | 1 |
| Abnet, CC | 1 |
| Kirsch, IR | 1 |
| Dawson, SJ | 1 |
| Michael, M | 1 |
| Biagi, J | 1 |
| Foo, KF | 1 |
| Jefford, M | 1 |
| Ngan, SY | 1 |
| Leong, T | 1 |
| Hui, A | 1 |
| Milner, AD | 1 |
| Thomas, RJ | 1 |
| Zalcberg, JR | 1 |
| Heath, EI | 1 |
| Canto, MI | 1 |
| Piantadosi, S | 1 |
| Montgomery, E | 1 |
| Weinstein, WM | 1 |
| Herman, JG | 1 |
| Dannenberg, AJ | 1 |
| Yang, VW | 1 |
| Shar, AO | 1 |
| Hawk, E | 1 |
| Forastiere, AA | 1 |
| Riley, M | 1 |
| Liu, X | 1 |
| Smalley, KJ | 1 |
| Guttridge, DC | 1 |
| Bolieva, LZ | 1 |
| Dzhioev, FK | 1 |
| Kakabadze, SA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Trial of Cisplatin, CPT-11, Celecoxib (PCC), Concurrent Radiation Therapy, and Surgery for Resectable Esophageal Cancer[NCT00137852] | Phase 2 | 35 participants (Actual) | Interventional | 2002-01-31 | Completed | ||
| Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention[NCT01192204] | Phase 1/Phase 2 | 41 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Chemoprevention for Barrett's Esophagus Trial (CBET)[NCT00005878] | Phase 2 | 0 participants | Interventional | 2000-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The remaining oral dysplasia lesion will be inspected at each follow up appointment (every 10-14 days). Biopsies will be immediately conducted on patients with any indication of malignant transformation including indurated, rolled borders, nonhealing ulcers, etc. Accordingly, these patients will withdraw from the trial. Participants will also be monitored for any changes consistent with contact mucositis e.g. soreness and erythema at application site. Clinical photographs were taken for the patients records. Pre treatment and post treatment photographs, with a ruler in place, were used for accurate pre and post treatment size measurement. NOTE: if treatment is beneficial, lesional size will decrease which will be reflected as a negative number. (NCT01192204)
Timeframe: pretreatment and posttreatment (3 months treatment duration)
| Intervention | mm^2 (Mean) |
|---|---|
| 10% FBR Gel | -26.12 |
| Placebo Gel | 18.12 |
Laboratory experiments will be conducted to assess the effects of gel treatment on pre and post loss of heterozygosity (LOH) events at loci associated with tumor suppressor genes. (NCT01192204)
Timeframe: Before and after the 3 month treatment duration
| Intervention | LOH events (Mean) |
|---|---|
| 10% FBR Gel | 0.9 |
| Placebo Gel | 0.4 |
A hemisection of lesional tissue will be conducted before the 3 month treatment to establish a diagnosis and provide a pretreatment baseline for the experimental parameters. Anl excisional biopsy of the treatment site including any remaining residual lesional tissue (excision of oral dysplastic lesions is consistent with current standards of care) will be obtained after 3 months of treatment to provide a posttreatment diagnosis. The 0 to 8 histologic scale was:0=normal with or without hyperkeratosis BEST OUTCOME, 1=atypia, 2=mild dysplasia, 3=mild-moderate dysplasia, 4=moderate dysplasia,5=moderate-severe dysplasia,6=severe dysplasia, 7=carcinoma in situ, 8=invasive oral squamous cell carcinoma (WORST OUTCOME). (NCT01192204)
Timeframe: Before and after the 3 month treatment.
| Intervention | unit on histologic grade scale (Mean) | |
|---|---|---|
| Pretreatment | Posttreatment | |
| 10% FBR Gel | 2.36 | 1.9 |
| Placebo Gel | 2.83 | 2.58 |
3 reviews available for celecoxib and Cancer of Esophagus
| Article | Year |
|---|---|
Combination of a COX-2 inhibitor with radiotherapy or radiochemotherapy in the treatment of thoracic cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cele | 2003 |
COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2003 |
[Anti-angiogenic therapy for gastrointestinal tumours].
Topics: Adult; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2005 |
10 trials available for celecoxib and Cancer of Esophagus
| Article | Year |
|---|---|
Oral metronomic chemotherapy after definitive chemoradiation in esophageal squamous cell carcinoma: a randomized clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Celecoxib; Chemoradiotherapy; Esophagea | 2022 |
The effect of celecoxib on DNA methylation of CDH13, TFPI2, and FSTL1 in squamous cell carcinoma of the esophagus in vivo.
Topics: Adult; Aged; Cadherins; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2 Inhibitors; DNA Methyl | 2016 |
Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2016 |
Serum cytokine analysis in a positive chemoprevention trial: selenium, interleukin-2, and an association with squamous preneoplastic disease.
Topics: Adult; Aged; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cyt | 2010 |
Preoperative taxane-based chemotherapy and celecoxib for carcinoma of the esophagus and gastroesophageal junction: results of a phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; | 2011 |
Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2004 |
Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib.
Topics: Adult; Aged; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Carcinoma, Squamous | 2005 |
Gene expression differences in normal esophageal mucosa associated with regression and progression of mild and moderate squamous dysplasia in a high-risk Chinese population.
Topics: Carcinoma, Squamous Cell; Celecoxib; China; Disease Progression; Double-Blind Method; Esophageal Neo | 2006 |
A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Celecoxib; Cisplatin; Combined Modality Therapy; | 2007 |
Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial.
Topics: Aged; Aged, 80 and over; Barrett Esophagus; Cadherins; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2 | 2007 |
18 other studies available for celecoxib and Cancer of Esophagus
| Article | Year |
|---|---|
OSU-03012, a non-Cox inhibiting celecoxib derivative, induces apoptosis of human esophageal carcinoma cells through a p53/Bax/cytochrome c/caspase-9-dependent pathway.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 9; Celecoxib; Cell Line, Tumor | 2013 |
A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; C | 2014 |
[Celecoxib antagonizes the cytotoxic effect of carboplatin in human esophageal cancer cells].
Topics: Apoptosis; Blotting, Western; Carboplatin; Caspase 3; Celecoxib; Cell Line, Tumor; Cell Survival; Dr | 2014 |
Celecoxib antagonizes the cytotoxicity of oxaliplatin in human esophageal cancer cells by impairing the drug influx.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Celecoxib | 2016 |
Chemoprevention and Barrett's esophagus: decisions, decisions.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cardiovascular Diseases; Celecoxib; Chemoprevention; Cyc | 2008 |
Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cardiovascular Diseases; Celecoxib; Chemoprevention; Cyc | 2008 |
Microsomal prostaglandin E synthase-1 inhibition blocks proliferation and enhances apoptosis in oesophageal adenocarcinoma cells without affecting endothelial prostacyclin production.
Topics: Adenocarcinoma; Apoptosis; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Endotheli | 2010 |
"War and Peace" with Barrett's esophagus.
Topics: Adenocarcinoma; Aged; Anti-Ulcer Agents; Antihypertensive Agents; Aspirin; Barrett Esophagus; Celeco | 2011 |
Celecoxib antagonizes the cytotoxicity of cisplatin in human esophageal squamous cell carcinoma cells by reducing intracellular cisplatin accumulation.
Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Cispla | 2011 |
Effect of Helicobacter pylori infection on Barrett's esophagus and esophageal adenocarcinoma formation in a rat model of chronic gastroesophageal reflux.
Topics: Adenocarcinoma; Anastomosis, Surgical; Animals; Barrett Esophagus; CDX2 Transcription Factor; Celeco | 2011 |
[An experimental study on chemoprevention of esophageal adenocarcinoma by celecoxib, a selective cyclooxygenase-2 inhibitor].
Topics: Adenocarcinoma; Animals; Barrett Esophagus; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, | 2012 |
Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis.
Topics: Adenocarcinoma; Anastomosis, Surgical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonat | 2004 |
Effect of chronic intake of NSAIDs and cyclooxygenase 2-selective inhibitors on esophageal cancer incidence.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control | 2004 |
Dietary zinc modulation of COX-2 expression and lingual and esophageal carcinogenesis in rats.
Topics: 4-Nitroquinoline-1-oxide; Animals; Apoptosis; Blotting, Western; Carcinogens; Carcinoma, Squamous Ce | 2005 |
[A COX-2 inhibitor suppresses esophageal inflammation-metaplasia-adenocarcinoma sequence in rats].
Topics: Adenocarcinoma; Animals; Apoptosis; Barrett Esophagus; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 | 2005 |
Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma.
Topics: Adenocarcinoma; Blotting, Western; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inh | 2005 |
Prevention of upper aerodigestive tract cancer in zinc-deficient rodents: inefficacy of genetic or pharmacological disruption of COX-2.
Topics: Animals; Carcinogens; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibi | 2008 |
Effects of acetylsalicylic acid and celecoxib on the N-nitrosodiethylamine induced carcinogenesis in rat liver and esophagus.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Celecoxib; Dieth | 2007 |